We have previously shown that blood-based metabolomics can accurately separate MS from controls and from AQP4-Ab NMOSD and MOG-Ab disease.2,43 The current study combines both approaches by using metabolomics to give pathologic support to the spontaneously separating clinico-radiologic phenotypes. This evidence concerns the gene AQP4 and myeloid sarcoma.